Marksans Pharma announced that its wholly owned subsidiary, Relonchem has received marketing approval from UK MHRA for the below mentioned products:1) Rasagiline Relonchem 1 mg Tablets2) Olmesartan 10 mg Film-coated Tablets3) Olmesartan 20 mg Film-coated Tablets4) Olmesartan 40 mg Film-coated TabletsPowered by Capital Market - Live News

Marksans Pharma announced that the Board of Directors of the Company at its meeting held on 30 May 2024, inter alia, have recommended the final dividend of Rs 0.6 per equity Share (i.e. 60%) , subject to the approval of the shareholders.Powered by Capital Market - Live News

Net profit of Marksans Pharma declined 4.44% to Rs 78.29 crore in the quarter ended March 2024 as against Rs 81.93 crore during the previous quarter ended March 2023. Sales rose 15.23% to Rs 560.01 crore in the quarter ended March 2024 as against Rs 485.98 crore during the previous quarter ended March 2023.For the full year,net profit rose 17.80% to Rs 313.70 crore in the year ended March 2024 as against Rs 266.31 crore during the previous year ended March 2023. Sales rose 17.56% to Rs 2177.41 crore in the year ended March 2024 as against Rs 1852.14 crore during the previous year ended March 2023. ParticularsQuarter EndedYear Ended�Mar. 2024Mar. 2023% Var.Mar. 2024Mar. 2023% Var. Sales560.01485.98 15 2177.411852.14 18 OPM %19.5822.54 -21.0618.32 - PBDT121.33118.12 3 497.80389.51 28 PBT100.28104.17 -4 423.53337.65 25 NP78.2981.93 -4 313.70266.31 18 Powered by Capital Market - Live News

Marksans Pharma announced that its wholly owned subsidiary, Relonchem has received marketing authorization for the product Levetiracetam Relonchem 100 mg/mL oral solution from UK MHRA. The product will be manufactured at the Group`s UK manufacturing facility. Powered by Capital Market - Live News

Marksans Pharma will hold a meeting of the Board of Directors of the Company on 30 May 2024Powered by Capital Market - Live News